Browsing Centre for Haemato-Oncology by Title
Now showing items 28-47 of 217
-
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.
(2017-11-22)Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we show that the CHK1 inhibitor (CHK1i) GDC-0575 enhances ... -
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
(Rockefeller University Press, 2019-03-19)Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the ... -
Dangerous power: mitochondria in CLL cells.
(American Society of Hematology, 2014-04-24) -
Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.
(2011-06)Clinical trials using vaccine measles virus (MV) as anticancer therapy are already underway. We compared the oncolytic potential of MV in two B-cell malignancies; adult acute lymphoblastic leukemia (ALL, an aggressive ... -
Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
(2018-02)Allogeneic haematopoietic stem-cell transplantation remains the only curative treatment for relapsed/refractory acute myeloid leukaemia (AML) and high-risk myelodysplasia but has previously been limited to patients who ...